BMC Cancer 2020 May 5
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Related Questions
If a patient presents with de novo oligometastatic (i.e., meeting STAMPEDE low met burden criteria) prostate cancer with no prior history of primary t...
New comment by Radiation Oncologist at UC San Diego ( November 28, 2024)
Great to hear! What is the trial? Can you point us to a protocol paper or website?